{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:15:57Z","timestamp":1776777357415,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["Grand Challenges in Global Health Initiative"],"award-info":[{"award-number":["Grand Challenges in Global Health Initiative"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["Grand Challenges in Global Health Initiative"],"award-info":[{"award-number":["Grand Challenges in Global Health Initiative"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["Grand Challenges in Global Health Initiative"],"award-info":[{"award-number":["Grand Challenges in Global Health Initiative"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["Grand Challenges in Global Health Initiative"],"award-info":[{"award-number":["Grand Challenges in Global Health Initiative"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["Grand Challenges in Global Health Initiative"],"award-info":[{"award-number":["Grand Challenges in Global Health Initiative"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["Grand Challenges in Global Health Initiative"],"award-info":[{"award-number":["Grand Challenges in Global Health Initiative"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adenoviral vectors are being developed as vaccines against infectious agents and tumour-associated antigens, because of their ability to induce cellular immunity. However, the protection afforded in animal models has not easily translated into primates and clinical trials, underlying the need for improving adenoviral vaccines-induced immunogenicity. A Toll-like receptor signalling molecule, TRAM, was assessed for its ability to modify the immune responses induced by an adenovirus-based vaccine. Different adenovirus vectors either expressing TRAM alone or co-expressing TRAM along with a model antigen were constructed. The modification of T-cell and antibody responses induced by TRAM was assessed <jats:italic>in vivo<\/jats:italic> in mice and in primates. Co-expression of TRAM and an antigen from adenoviruses increased the transgene-specific CD8+ T cell responses in mice. Similar effects were seen when a TRAM expressing virus was co-administered with the antigen-expressing adenovirus. However, in primate studies, co-administration of a TRAM expressing adenovirus with a vaccine expressing the ME-TRAP malaria antigen had no significant effect on the immune responses. While these results support the idea that modification of innate immune signalling by genetic vectors modifies immunogenicity, they also emphasise the difficulty in generalising results from rodents into primates, where the regulatory pathway may be different to that in mice.<\/jats:p>","DOI":"10.1038\/s41598-020-61730-8","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T10:03:41Z","timestamp":1585649021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule"],"prefix":"10.1038","volume":"10","author":[{"given":"Christine S.","family":"Rollier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7958-6961","authenticated-orcid":false,"given":"Alexandra J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Colbjorn","family":"Sogaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared","family":"Honeycutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Furze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Migena","family":"Bregu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9750","authenticated-orcid":false,"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wyllie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-9629","authenticated-orcid":false,"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"61730_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev-med-051214-024241","volume":"67","author":"PJ Hotez","year":"2016","unstructured":"Hotez, P. J., Bottazzi, M. E. & Strych, U. New Vaccines for the World\u2019s Poorest People. Annu. Rev. Med. 67, 405\u2013417, https:\/\/doi.org\/10.1146\/annurev-med-051214-024241 (2016).","journal-title":"Annu. Rev. Med."},{"key":"61730_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"N Tatsis","year":"2004","unstructured":"Tatsis, N. & Ertl, H. C. Adenoviruses as vaccine vectors. Mol. therapy: J. Am. Soc. Gene Ther. 10, 616\u2013629, https:\/\/doi.org\/10.1016\/j.ymthe.2004.07.013 (2004).","journal-title":"Mol. therapy: J. Am. Soc. Gene Ther."},{"key":"61730_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","volume":"41","author":"KJ Ewer","year":"2016","unstructured":"Ewer, K. J. et al. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr. Opin. immunology 41, 47\u201354, https:\/\/doi.org\/10.1016\/j.coi.2016.05.014 (2016).","journal-title":"Curr. Opin. immunology"},{"key":"61730_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04859-5","volume":"9","author":"C Lopez-Camacho","year":"2018","unstructured":"Lopez-Camacho, C. et al. Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat. Commun. 9, 2441, https:\/\/doi.org\/10.1038\/s41467-018-04859-5 (2018).","journal-title":"Nat. Commun."},{"key":"61730_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","volume":"23","author":"CS Rollier","year":"2011","unstructured":"Rollier, C. S., Reyes-Sandoval, A., Cottingham, M. G., Ewer, K. & Hill, A. V. Viral vectors as vaccine platforms: deployment in sight. Curr. Opin. immunology 23, 377\u2013382, https:\/\/doi.org\/10.1016\/j.coi.2011.03.006 (2011).","journal-title":"Curr. Opin. immunology"},{"key":"61730_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/ni1077","volume":"5","author":"O Alpan","year":"2004","unstructured":"Alpan, O., Bachelder, E., Isil, E., Arnheiter, H. & Matzinger, P. \u2018Educated\u2019 dendritic cells act as messengers from memory to naive T helper cells. Nat. Immunol. 5, 615\u2013622, https:\/\/doi.org\/10.1038\/ni1077 (2004).","journal-title":"Nat. Immunol."},{"key":"61730_CR7","doi-asserted-by":"publisher","unstructured":"Newton, K. & Dixit, V. M. Signaling in innate immunity and inflammation. Cold Spring Harbor perspectives in biology 4, https:\/\/doi.org\/10.1101\/cshperspect.a006049 (2012).","DOI":"10.1101\/cshperspect.a006049"},{"key":"61730_CR8","doi-asserted-by":"publisher","first-page":"6090","DOI":"10.4049\/jimmunol.1401605","volume":"193","author":"J Stack","year":"2014","unstructured":"Stack, J. et al. TRAM is required for TLR2 endosomal signaling to type I IFN induction. J. immunology 193, 6090\u20136102, https:\/\/doi.org\/10.4049\/jimmunol.1401605 (2014).","journal-title":"J. immunology"},{"key":"61730_CR9","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1074\/jbc.M114.593426","volume":"290","author":"NJ Nilsen","year":"2015","unstructured":"Nilsen, N. J. et al. A role for the adaptor proteins TRAM and TRIF in toll-like receptor 2 signaling. J. Biol. Chem. 290, 3209\u20133222, https:\/\/doi.org\/10.1074\/jbc.M114.593426 (2015).","journal-title":"J. Biol. Chem."},{"key":"61730_CR10","doi-asserted-by":"publisher","first-page":"e42388","DOI":"10.1371\/journal.pone.0042388","volume":"7","author":"DH Wyllie","year":"2012","unstructured":"Wyllie, D. H. et al. Identification of 34 novel proinflammatory proteins in a genome-wide macrophage functional screen. PLoS one 7, e42388, https:\/\/doi.org\/10.1371\/journal.pone.0042388 (2012).","journal-title":"PLoS one"},{"key":"61730_CR11","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1016\/j.vaccine.2009.07.025","volume":"27","author":"KC Larsen","year":"2009","unstructured":"Larsen, K. C. et al. Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. Vaccine 27, 5589\u20135598, https:\/\/doi.org\/10.1016\/j.vaccine.2009.07.025 (2009).","journal-title":"Vaccine"},{"key":"61730_CR12","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1093\/nar\/18.17.5322","volume":"18","author":"S Mizushima","year":"1990","unstructured":"Mizushima, S. & Nagata, S. pEF-BOS, a powerful mammalian expression vector. Nucleic acids Res. 18, 5322 (1990).","journal-title":"Nucleic acids Res."},{"key":"61730_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/bit.24342","volume":"109","author":"MG Cottingham","year":"2012","unstructured":"Cottingham, M. G. et al. Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnol. Bioeng. 109, 719\u2013728, https:\/\/doi.org\/10.1002\/bit.24342 (2012).","journal-title":"Biotechnol. Bioeng."},{"key":"61730_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","volume":"211","author":"SH Hodgson","year":"2015","unstructured":"Hodgson, S. H. et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J. Infect. Dis. 211, 1076\u20131086, https:\/\/doi.org\/10.1093\/infdis\/jiu579 (2015).","journal-title":"J. Infect. Dis."},{"key":"61730_CR15","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1128\/JVI.70.7.4805-4810.1996","volume":"70","author":"C Chartier","year":"1996","unstructured":"Chartier, C. et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. virology 70, 4805\u20134810 (1996).","journal-title":"J. virology"},{"key":"61730_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nm881","volume":"9","author":"SJ McConkey","year":"2003","unstructured":"McConkey, S. J. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9, 729\u2013735, https:\/\/doi.org\/10.1038\/nm881 (2003).","journal-title":"Nat. Med."},{"key":"61730_CR17","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1128\/jvi.00171-06","volume":"80","author":"NA Wilson","year":"2006","unstructured":"Wilson, N. A. et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. virology 80, 5875\u20135885, https:\/\/doi.org\/10.1128\/jvi.00171-06 (2006).","journal-title":"J. virology"},{"key":"61730_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.trsl.2014.08.006","volume":"165","author":"PD Burbelo","year":"2015","unstructured":"Burbelo, P. D., Lebovitz, E. E. & Notkins, A. L. Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Transl. research: J. laboratory Clin. Med. 165, 325\u2013335, https:\/\/doi.org\/10.1016\/j.trsl.2014.08.006 (2015).","journal-title":"Transl. research: J. laboratory Clin. Med."},{"key":"61730_CR19","doi-asserted-by":"publisher","first-page":"e44943","DOI":"10.1371\/journal.pone.0044943","volume":"7","author":"EK Forbes","year":"2012","unstructured":"Forbes, E. K. et al. T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein. PLoS one 7, e44943, https:\/\/doi.org\/10.1371\/journal.pone.0044943 (2012).","journal-title":"PLoS one"},{"key":"61730_CR20","doi-asserted-by":"publisher","first-page":"286re285","DOI":"10.1126\/scitranslmed.aaa2373","volume":"7","author":"C Ogwang","year":"2015","unstructured":"Ogwang, C. et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci. Transl. Med. 7, 286re285, https:\/\/doi.org\/10.1126\/scitranslmed.aaa2373 (2015).","journal-title":"Sci. Transl. Med."},{"key":"61730_CR21","doi-asserted-by":"publisher","first-page":"e105520","DOI":"10.1371\/journal.pone.0105520","volume":"9","author":"AJ Spencer","year":"2014","unstructured":"Spencer, A. J. et al. 4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques. PLoS one 9, e105520, https:\/\/doi.org\/10.1371\/journal.pone.0105520 (2014).","journal-title":"PLoS one"},{"key":"61730_CR22","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1099\/vir.0.006833-0","volume":"90","author":"L O\u2019Brien","year":"2009","unstructured":"O\u2019Brien, L. et al. Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J. Gen. Virol. 90, 874\u2013882, https:\/\/doi.org\/10.1099\/vir.0.006833-0 (2009).","journal-title":"J. Gen. Virol."},{"key":"61730_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ni.1727","volume":"10","author":"EM Palsson-McDermott","year":"2009","unstructured":"Palsson-McDermott, E. M. et al. TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway. Nat. Immunol. 10, 579\u2013586, https:\/\/doi.org\/10.1038\/ni.1727 (2009).","journal-title":"Nat. Immunol."},{"key":"61730_CR24","doi-asserted-by":"publisher","first-page":"e33555","DOI":"10.1371\/journal.pone.0033555","volume":"7","author":"AJ Spencer","year":"2012","unstructured":"Spencer, A. J. et al. Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS one 7, e33555, https:\/\/doi.org\/10.1371\/journal.pone.0033555 (2012).","journal-title":"PLoS one"},{"key":"61730_CR25","doi-asserted-by":"publisher","first-page":"e100538","DOI":"10.1371\/journal.pone.0100538","volume":"9","author":"AJ Spencer","year":"2014","unstructured":"Spencer, A. J. et al. Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain. PLoS one 9, e100538, https:\/\/doi.org\/10.1371\/journal.pone.0100538 (2014).","journal-title":"PLoS one"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61730-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T08:51:37Z","timestamp":1670316697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61730-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["61730"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-61730-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.V.S.H. and S.G.C. are names as co-inventors on patents related to recombinant viral vectors for malaria and other indications.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5716"}}